Immunome climbs as Stifel initiates coverage

** Immunome IMNM.O shares up 1.85% premarket

** Stifel initiates oncology drugmaker's stock with "hold" rating

** Brokerage's $24 PT marks 11.6% upside to last close

** Experimental desmoid-tumor drug varegacestat hardly differs from rival SpringWorks' approved Ogsiveo in effectiveness, pain relief and convenience - Stifel

** Says advanced targeted cancer drugs, led by IM-1021, show promise but need more clinical results

** Those products deliver cancer-killing drugs directly to cancer cells, while limiting damage to healthy cells

** Average rating of 16 analysts is "buy"; median PT $35.50 - data compiled by LSEG

** IMNM largely flat YTD